Last reviewed · How we verify
Bortezomib-Rituximab-Bendamustine
Bortezomib-Rituximab-Bendamustine is a combination of a proteasome inhibitor, a monoclonal antibody, and a chemotherapy agent.
Bortezomib-Rituximab-Bendamustine is a combination of a proteasome inhibitor, a monoclonal antibody, and a chemotherapy agent. Used for Relapsed or refractory mantle cell lymphoma.
At a glance
| Generic name | Bortezomib-Rituximab-Bendamustine |
|---|---|
| Also known as | BRB |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | Proteasome inhibitor, Monoclonal antibody, Chemotherapy agent |
| Target | CD20, Proteasome |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bortezomib targets the proteasome, disrupting cell growth and survival. Rituximab targets CD20 on B cells, leading to their depletion. Bendamustine is a chemotherapy agent that interferes with DNA replication and repair.
Approved indications
- Relapsed or refractory mantle cell lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma (PHASE2)
- Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma (PHASE2)
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (PHASE1)
- Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's (PHASE2)
- Tumor Registry of Lymphatic Neoplasia
- Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma (PHASE2)
- Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma (PHASE2)
- Study of Mantle Cell Lymphoma Treatment by RiBVD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: